Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. BJS 2018; 105: 946-958.
Published: 30th April 2018
Authors: E. Versteijne, J. A. Vogel, M. G. Besselink, O. R. C. Busch, J. W. Wilmink, J. G. Daams et al.
Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery
MEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer treated with or without neoadjuvant treatment. Secondary outcomes included overall and R0 resection rate, pathological lymph node rate, reasons for unresectability and toxicity of neoadjuvant treatment.
In total, 38 studies were included with 3484 patients, of whom 1738 (49·9 per cent) had neoadjuvant treatment. The weighted median overall survival by intention to treat was 18·8 months for neoadjuvant treatment and 14·8 months for upfront surgery; the difference was larger among patients whose tumours were resected (26·1
Neoadjuvant treatment appears to improve overall survival by intention to treat, despite lower overall resection rates for resectable or borderline resectable pancreatic cancer.Full text
You may also be interested in
Evaluating the collection, comparability and findings of six global surgery indicators. BJS 2019; 106: e138-e150.
Authors: H. Holmer, A. Bekele, L. Hagander, E. M. Harrison, P. Kamali, J. S. Ng‐Kamstra et al.
Cost‐effectiveness analysis of a multicentre randomized clinical trial comparing surgery with conservative management for recurrent and ongoing diverticulitis (DIRECT trial).
Authors: H. E. Bolkenstein, G. A. de Wit, E. C. J. Consten, B. J. M. Van de Wall, I. A. M. J. Broeders, W. A. Draaisma et al.
Notes: Maintained benefits
Validation of the Bluebelle Wound Healing Questionnaire for assessment of surgical‐site infection in closed primary wounds after hospital discharge.
Authors: Rhiannon Macefield, Jane Blazeby, Barnaby Reeves, Sara Brookes, Kerry Avery, Chris Rogers et al.
Notes: Simple and valid
Authors: K. Søreide, D. C. Winter
Randomized clinical trial
Randomized trial of two types of gastrojejunostomy after pancreatoduodenectomy and risk of delayed gastric emptying (PAUDA trial). BJS 2019; 106: 46-54.
Authors: J. Busquets, S. Martín, J. Fabregat, L. Secanella, N. Pelaez, E. Ramos et al.
Notes: No difference in outcomes
Authors: R. D. Staiger, H. Schwandt, M. A. Puhan, P.‐A. Clavien
Authors: S. Wiig, C. Macrae
Authors: F. Dossa, N. N. Baxter
Effect of preoperative biliary drainage on cholestasis‐associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma. BJS 2019; 106: 55-58.
Authors: M. J. Reiniers, L. de Haan, R. Weijer, J. K. Wiggers, A. Jongejan, P. D. Moerland et al.
Authors: S. M. L. de Mik, F. E. Stubenrouch, R. Balm, D. T. Ubbink
Notes: Heterogeneous data
Authors: M. L. Nicholson, C. Yong, P. B. Trotter, L. Grant, S. A. Hosgood
Notes: Rare, but predictable
Meta‐analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes.
Authors: M. Roman, A. Monaghan, G. F. Serraino, D. Miller, S. Pathak, F. Lai et al.
Notes: Possible but how much is enough?